Genincode PLC (GENIG)

Currency in GBP
1.00
+0.05(+5.26%)
Closed·
Advertisement
GENIG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.851.00
52 wk Range
0.805.50
Key Statistics
Bid/Ask
0.85 / 1.15
Prev. Close
0.95
Open
0.9
Day's Range
0.85-1
52 wk Range
0.8-5.5
Volume
1.37M
Average Volume (3m)
7.59M
1-Year Change
-55.5556%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GENIG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.50
Upside
+650.00%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Genincode PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.50
(+650.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
08/06/2026
EPS / Forecast
-0.01 / --
Revenue / Forecast
1.47M / --
EPS Revisions
Last 90 days

Compare GENIG to Peers and Sector

Metrics to compare
GENIG
Peers
Sector
Relationship
P/E Ratio
−1.3x−0.4x−0.4x
PEG Ratio
−0.070.000.00
Price/Book
57.7x1.0x2.6x
Price / LTM Sales
2.3x0.6x3.0x
Upside (Analyst Target)
-57.0%57.3%
Fair Value Upside
Unlock22.2%8.9%Unlock

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient’s health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart diseases, such as cardiomyopathies, channelopathies, and aortopathies related with sudden cardiac death syndrome. It also provides THROMBO inCode, a genetic test for the diagnosis of hereditary thrombophilia and for assessing the patient's risk of thrombosis; THROMBO inCode reproductive health, a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and risk of ovarian cancer algorithm test product. In addition, the company is involved in Medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
89.07M11.83%801.64K
Other Institutional Investors
513.66M68.21%4.62M
Public Companies & Retail Investors
150.31M19.96%1.35M
Total
753.04M100.00%6.78M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Santi 1990, S.L.11.41%85,940,587773
Octopus Investments Limited7.02%52,877,293476

FAQ

What Is the Genincode (London: GENIG) Share Price Today?

The Genincode stock price today is 1.00 GBP.

What Stock Exchange Does Genincode (GENIG) Trade On?

Genincode is listed and trades on the London Stock Exchange.

What Is the Ticker (Stock Symbol) for Genincode?

The stock symbol (also called a 'ticker') for Genincode is "GENIG."

What Is the Current Genincode Market Capitalisation?

As of today, Genincode (London: GENIG) market cap is 7.15M GBP.

What Is Genincode's (GENIG) Earnings Per Share (TTM)?

The Genincode EPS is currently -0.02 (Trailing Twelve Months).

When Is the Next Genincode Earnings Date?

Genincode's next earnings report will be released on 08/06/2026.

Is GENIG a Buy or Sell From a Technical Analyst Perspective?

Based on today's Genincode moving averages and other technical indicators, the daily buy/sell signal for GENIG stock is Sell.

How Many Times Has Genincode Stock Split?

Genincode has split 0 times. (See the GENIG stock split history page for full effective split date and price information.)

How Many Employees Does Genincode Have?

Genincode has 44 employees, based on their latest Companies House report.

What is the current trading status of Genincode (London: GENIG)?

As of 24/06/2026, Genincode (GENIG) is trading at a share price of 1.00 GBP, with a previous close of 0.95 GBP. The stock has fluctuated within a day range of 0.85 GBP to 1.00 GBP, while its 52-week range spans from 0.80 GBP to 5.50 GBP.

What Is Genincode (GENIG) Price Target According to Analysts?

The average 12-month price target for Genincode is 7.50 GBP, with a high estimate of 7.5 GBP and a low estimate of 7.5 GBP. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +650.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.